Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy—a randomized controlled pilot trial

Streckmann, Fiona; Lehmann, Helmar C.; Balke, Maryam; Schenk, Alexander; Oberste, Max; Heller, Alicia; Schürhörster, Anne; Elter, Thomas; Bloch, Wilhelm; Baumann, Freerk T.

doi:10.1007/s00520-018-4531-4

Cited by 81 publications

(94 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To ensure the quality of reporting WBV treatment trials biomechanical parameters such as frequency, peak-to-peak displacement or periodicity of the sessions have been defined [31] , [32] . Many findings confirm safety and feasibility as well as efficacy of low-magnitude high-frequency WBV for improving physical performance in healthy subjects as well as in adult patients with chronic diseases, chemotherapy-induced peripheral neuropathy as well as pediatric cancer patients [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] . More recently, favorable effects of WBV on quality of life, physical functioning, and fatigue were evidenced in patients with hematological malignancies [41] , [42] .…”

Section: Introductionmentioning

confidence: 59%

Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance

Seefried

Genest

Strömsdörfer

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 59%

Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance

Seefried

Genest

Strömsdörfer

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…Based on pilot results, a medium effect for the primary endpoint can be expected. In this randomised, controlled pilot study,18 the FACT/GOG-Ntx sum score changed by 24% (16.8±8.1 to 12.8±7.8) after 6 weeks of WBV training in 10 oncological patients, whereas the control group remained similar. Based on this pilot study, medium effect sizes seem also a realistic and relevant estimate for several of the secondary outcomes (eg, postural balance, pain).…”

Section: Methodsmentioning

confidence: 83%

“…WBV and sensorimotor training proved feasible for patients with CIPN. In addition, both exercise groups benefited (improved reflex activity, balance control and subjective reduction of symptoms) from 6 weeks of intervention twice a week 18. We consequently intend to further investigate the potentially beneficial effects of WBV in a randomized controlled trial (RCT).…”

Section: Introductionmentioning

confidence: 99%

Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial—VANISH

Streckmann

Hess²,

Bloch³

et al. 2019

BMJ Open

Self Cite

View full text Add to dashboard Cite

IntroductionChemotherapy-induced peripheral neuropathy (CIPN) is a prevalent and clinically meaningful side effect of cancer treatment. CIPN is induced by neurotoxic agents, causing severe sensory and/or motor deficits, resulting in disability and poor recovery, reducing patients’ quality of life and limiting medical therapy. To date, effective treatment options are lacking. Whole-body vibration (WBV) training can attenuate motor and sensory deficits. We are conducting a two-armed, multicentre, assessor-blinded, randomised controlled trial, to investigate the effects of WBV on relevant symptoms of CIPN and determine the training characteristics.Methods and analysisIn this ongoing study, 44 patients who have completed therapy in the past 3 months, with a neurologically confirmed CIPN are assessed before and after a 12-week intervention and follow-up. The intervention group receives WBV twice a week. Exercises are individually tailored according to the initially determined optimal neuromuscular response. The control group receives care as usual.Primary endpoint is the patient reported reduction of CIPN-related symptoms (Functional Assessment of Cancer Therapy/Gynaecology Oncology Group—Neurotoxicity). Secondary endpoints are compound muscle action potentials, distal motor latency, conduction velocity, F-waves from the tibial and peroneal nerve, antidromic sensory nerve conduction studies of the sural nerve, normalised electromyographic activity, peripheral deep sensitivity, proprioception, balance, pain, the feasibility of training settings, quality of life and the level of physical activity.Aim, ethics and disseminationThe study was approved by both responsible ethics committees. (1) Our results may contribute to a better understanding of the effects of WBV on motor and sensory functions and (2) may provide information whether WBV at the most effective setting, is feasible for neuropathic patients. (3) Our results may also contribute to improve supportive care in oncology, thereby enhancing quality of life and enabling the optimal medical therapy. All results will be published in international peer-reviewed journals as well as a manual for clinical practice.Trial registration numberNCT03032718

show abstract

“…These symptoms can be classified as a motor or sensory impairments. These impairments typically include sensory axonal peripheral neuropathy ('stocking and glove' neuropathy), which is accompanied by numbness, paresthesias, ongoing/spontaneous pain hypersensitivity to mechanical and thermal stimuli in the hands and feet [17], and motor symptoms such as distal weakness, reduced or absent Achilles tendon reflexes, paresthesias, breath dysregulation, abnormal swallowing, laryngospasm, muscle cramps, jaw stiffness, visual field changes, muscle weakness, reduced balance control and insecure gait, the mechanisms of which are not fully understood [20,33,40,41].…”

Section: Symptoms Of Cipnmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

Sałat

2020

Pharmacol. Rep

View full text Add to dashboard Cite

Background Despite the increasing knowledge of the etiology of neuropathic pain, this type of chronic pain is resistant to available analgesics in approximately 50% of patients and therefore is continuously a subject of considerable interest for physiologists, neurologists, medicinal chemists, pharmacologists and others searching for more effective treatment options for this debilitating condition. Materials and methods The present review article is the first of the two articles focused on chemotherapy-induced peripheral neuropathy (CIPN). Results CIPN is regarded as one of the most common drug-induced neuropathies and is highly pharmacoresistant. The lack of efficacious pharmacological methods for treating CIPN and preventing its development makes CIPN-related neuropathic pain a serious therapeutic gap in current medicine and pharmacotherapy. In this paper, the most recent advances in the field of studies on CIPN caused by platinum compounds (namely oxaliplatin and cisplatin), taxanes, vinca alkaloids and bortezomib are summarized. Conclusions The prevalence of CIPN, potential causes, risk factors, symptoms and molecular mechanisms underlying this pharmacoresistant condition are discussed.

show abstract

Sensorimotor training and whole-body vibration training have the potential to reduce motor and sensory symptoms of chemotherapy-induced peripheral neuropathy—a randomized controlled pilot trial

Cited by 81 publications

References 34 publications

Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance

Impact of whole-body vibration exercise on physical performance and bone turnover in patients with monoclonal gammopathy of undetermined significance

Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial—VANISH

Chemotherapy-induced peripheral neuropathy: part 1—current state of knowledge and perspectives for pharmacotherapy

Contact Info

Product

Resources

About